BioNTech have announced at this week's virtual J.P. Morgan Healthcare Conference that it is increasing its 2021 delivery target for its Covid-19 vaccine comirnaty, co-developed with Pfizer, to 2 billion doses, up from 1.3 billion doses.
Because low dead space syringes allow for the extraction of an additional dose from a standard vial, the biotech company has upped its projections based on this six-dose label.
The company is also boasting a new manufacturing site in Marburg, Germany, that it acquired from Novartis in September and which will become operational at the end of February.. BioNTech says that facility will boost annual capacity by up to 750 million doses.
The company revealed that 32.9 million doses had been shipped as of Sunday, January 10.
During its presentation, BioNTech CEO Ugur Sahin said the company will publish data over the next 10 days on how well the vaccine will likely protect against the variants discovered in Britain and South Africa.
Read the Reuters report